Accelerate Oncology Research with Genomic Data
Most cancer care occurs outside of experimental settings, but patient genomic data isn’t typically used to inform brand or research strategies. Genospace addresses this market gap by leveraging next-generation sequencing (NGS) patient data to generate valuable, updated market and Precision Insight Reports. Because real-world evidence is vital to the understanding of the role of genomics in cancer progression and therapeutic interaction.
Empowering oncology breakthroughs with real-world (RWD) and insights
Extract, harmonize, and analyze clinical-genomic data to provide large-scale, real-world insights into the molecular landscape of oncology
Leverage longitudinal analyses
Gain insights into sociodemographic characteristics, molecular testing patterns and results, therapeutic summaries and clinical outcomes in real-world settings stratified by in/out cohort and practice.
Discover precision insights
Generate detailed summaries of disease-relevant biomarkers and frequencies, together with common, co-occurring mutations.
Make feasibility predictions
Assess data availability and landscape across structured and unstructured variables to evaluate the statistical power and feasibility of conducting your HEOR study with Ontada.
Create stratified reports
Produce a series of pre-defined reports with a regular update cadence stratified by disease/histological subgroup, line of therapy, practice/physician and other metrics.
Perform an outcome analysis
Create detailed therapeutic summaries and statistical analyses, including time to next treatment analyses for the top 20 therapies used in the cohort.
Generate care insights
Assess practice-level testing patterns and timing about treatment initiation.
Expand your understanding of the oncology landscape by leveraging NGS data generated where most patients receive their care. Contact a Genospace expert to learn how Ontada can accelerate precision oncology treatment and therapies.